ProMIS Neurosciences

About ProMIS Neurosciences

ProMIS Neurosciences Inc. is a publicly traded, clinical-stage biotechnology company developing therapeutic antibodies for neurodegenerative diseases. Founded in 2004 by Dr. Neil Cashman and Vigen Nazarian, the company is headquartered in Toronto, Canada, with offices in Cambridge, Massachusetts. Dr. Cashman, a physician and scientist with extensive experience in neurodegenerative diseases, serves as the Chief Scientific Officer and developed the company's core technology. His research in protein misfolding diseases forms the scientific foundation of the company. Neil Warma became the interim CEO in January 2024, bringing over 25 years of experience as a healthcare entrepreneur.

ProMIS operates in the biotechnology market, focusing on precision medicine for conditions like Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), multiple system atrophy (MSA), and Parkinson's disease (PD). The company's business model centers on the discovery and development of its pipeline candidates to address significant unmet needs in neurodegenerative disease treatment. As a clinical-stage company, its revenue model is not yet based on product sales but on securing funding through investments and partnerships to advance its research and clinical trials. The company has raised capital through numerous funding rounds, including a significant private investment in public equity (PIPE) financing of up to $175 million in January 2026, which is expected to extend its cash runway into 2028. The company is listed on the NASDAQ stock exchange under the ticker symbol PMN.

The company's core technology is its proprietary computational discovery engine, which includes platforms like EpiSelect™ and Collective Coordinates. This engine uses artificial intelligence and computational modeling to predict and identify unique targets, known as Disease Specific Epitopes (DSEs), on the surface of toxic misfolded proteins (oligomers) that are the root cause of several neurodegenerative diseases. This approach allows for the creation of highly selective antibodies that target only the harmful toxic oligomers, leaving the normal, functional proteins unharmed, which is a key differentiator intended to enhance safety and efficacy.

ProMIS's lead product candidate is PMN310, a humanized monoclonal antibody designed for the treatment of Alzheimer's disease by selectively targeting toxic amyloid-beta oligomers (AβO). By avoiding binding to plaque, PMN310 aims to reduce the risk of amyloid-related imaging abnormalities (ARIA), a common side effect of other AD therapies. PMN310 has received Fast Track designation from the U.S. FDA and is currently in a Phase 1b clinical trial (PRECISE-AD) to evaluate its safety, tolerability, and pharmacokinetics in patients with early Alzheimer's disease. The company expects to report interim data from this trial in mid-2026 and top-line results toward the end of 2026. Other pipeline candidates include PMN267 for ALS and PMN442 for MSA, as well as vaccine programs for AD and Parkinson's.